Adding antibodies to enhance photodynamic therapy for viral and bacterial disease

Photodynamic therapy, or using light to inactivate viruses, bacteria, and other microbes, has garnered promising results in recent decades for treating respiratory tract infections and some types of cancer. Researchers review the existing approaches and propose adding antibodies to enhance PDT efficacy. They provide a model to help expedite overall PDT development as a rapid response to emergent viral pandemic threats.